α-Lipoic acid (ALA) is an organosulfur compound featuring a five-membered 1,2-dithiolane ring and a distinctive amphiphilic distribution profile. It can undergo a reversible redox cycle between oxidized lipoic acid and reduced dihydrolipoic acid (DHLA). This structure–function coupling underpins its dual significance as (i) a key covalently bound cofactor in mitochondrial multienzyme complexes (e.g., pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes) and (ii) a versatile redox-active ingredient with radical-scavenging capacity, antioxidant-network regeneration, and metal-ion chelation potential. These attributes support broad deployment across pharmaceuticals, dietary supplements, cosmetics, and animal nutrition, where consistent quality, stereochemical control, and formulation-stability engineering are central to scalable implementation.
Keywords: lipoic acid; dihydrolipoic acid; 1,2-dithiolane; chiral purification; quality control; antioxidant; drug delivery
I. Core Technical Characteristics of α-Lipoic Acid
1.1 Chemical Structure and Physicochemical Properties
α-Lipoic acid is chemically named 5-(1,2-dithiolan-3-yl)pentanoic acid, with molecular formula C₈H₁₄O₂S₂ and relative molecular mass of approximately 206.33. Its core motif is an intramolecular disulfide ring (1,2-dithiolane), which can be reversibly converted between the oxidized state (cyclic disulfide) and the reduced state (two thiols). This reversibility provides the structural basis for its redox activity and cofactor functionality.
(1) Appearance and Solubility
① Typically a yellow to pale-yellow crystalline powder.
② Limited solubility in water, with better solubility in alcohols and many organic solvents; in formulation engineering, water-phase compatibility is commonly improved via salt formation, complexation, inclusion complexes, or carrier-based approaches.
(2) Stability Profile
① Photosensitive and prone to photodegradation and oxidative side reactions; storage is typically under light protection, sealed packaging, and low-temperature conditions.
② Relatively stable under acidic conditions, while degradation and side reactions are more likely in alkaline media; formulation systems should control the pH window and minimize catalytic sources such as trace metals.
(3) Chirality and Stereochemical Differences
① α-Lipoic acid contains a stereogenic center. In biological systems, the naturally occurring form is predominantly R-(+), and it is generally regarded as having higher biological activity and stronger affinity for native enzyme systems.
② Industrial products are commonly racemic (R/S mixtures). For high-end pharmaceutical or application-specific grades, tighter control of R-content and optical purity is often required.
1.2 Redox Cycling and Antioxidant-Network Effects
The ALA/DHLA pair forms a reversible redox couple that participates in antioxidative regulation across multiple oxidative-stress contexts in and outside cells.
(1) Direct Scavenging of Reactive Oxygen/Nitrogen Species
① It can participate in suppressing chain-reaction products associated with hydroxyl radicals and superoxide-related processes, thereby reducing risks of lipid peroxidation and protein oxidation.
(2) Regeneration of Antioxidant Networks
① DHLA is a strong reductant and can contribute to the regeneration of glutathione, vitamin C, and vitamin E pools, enhancing the persistence of the overall antioxidant network.
(3) Metal-Ion Chelation and Suppression of Catalytic Oxidation
① By chelating certain transition-metal ions, it can reduce the risk of metal-catalyzed oxidative chain reactions and indirectly mitigate oxidative damage.
1.3 Cofactor Function and Biocatalytic Significance in Metabolism
The biological value of α-lipoic acid arises not only from redox regulation but also from its role in metabolic coupling within energy-metabolism multienzyme complexes.
(1) Acyl Transfer and Reducing-Equivalent Shuttling
① In mitochondrial multienzyme complexes, lipoic acid is covalently attached to specific lysine residues on designated enzyme subunits and functions as a “swinging arm” to transfer acyl groups and reducing equivalents between active sites.
② Via reversible interconversion between disulfide and dithiol states, it couples acyl transfer with redox hydrogen transfer.
(2) Stereochemistry and Enzyme Affinity
① Because enzyme active sites exhibit stereoselectivity, the R-form is generally considered more compatible with recognition and catalysis in native enzyme systems, which motivates tighter optical-purity control for certain high-end applications.
II. Preparation Process Technologies for α-Lipoic Acid
2.1 Chemical Synthesis Routes and Key Process-Control Elements
Industrial production is predominantly based on chemical synthesis. The principal technical challenges include constructing the 1,2-dithiolane ring, suppressing side reactions and impurity growth, and implementing chiral separation or asymmetric synthesis when required.
(1) Key Route-Design Logic
① Build the pentanoic acid side-chain skeleton from an appropriate carbon-chain precursor.
② Introduce sulfur functionalities and close the disulfide ring to form the 1,2-dithiolane motif.
③ Complete hydrolysis, acidification, and purification to obtain α-lipoic acid.
(2) Process-Control Priorities
① Disulfide formation is sensitive to the redox environment; oxidant/reductant equivalents and reaction temperature should be controlled to avoid over-oxidation or over-reduction that drives impurity accumulation.
② Strict control of trace metals, light exposure, and solvent quality helps suppress side reactions and color deepening.
③ Refining strategies are implemented to limit characteristic impurities (e.g., polysulfide cyclic byproducts or over-sulfurized species) and maintain a stable, controllable impurity profile.
(3) Yield and Scale-Up Considerations
① In scale-up, mass-transfer and heat-release management strongly influence selectivity and the impurity profile.
② Solvent recovery and compliant treatment of salt streams and sulfur-containing effluents are central to both cost control and regulatory readiness.
2.2 Chiral Control and Strategies for R-(+)-α-Lipoic Acid
For high-R-content products, mainstream engineering strategies commonly center on “resolution–recrystallization–chiral purification” or on asymmetric synthesis/biocatalysis.
(1) Chiral Resolution and Purification
① R/S separation can be achieved by forming diastereomeric salts or using chiral resolving agents, followed by de-salting and polishing to obtain products with high optical purity.
② Chiral HPLC can support high-purity preparation and batch release; however, scale-up economics must balance cost, solvent consumption, and throughput.
(2) Asymmetric Synthesis and Biocatalysis
① Enantioselective catalytic or enzymatic routes can reduce resolution losses and improve atom economy.
② Industrialization depends on catalyst robustness, substrate scope, and simplified downstream processing.
2.3 Biosynthesis and Green-Manufacturing Trends
Biosynthetic routes typically rely on microbial metabolic pathways and lipoic-acid synthase systems. While offering green potential, they commonly face limitations in titer, productivity, and downstream purification cost.
(1) Key Bottlenecks
① Insufficient fermentation titers and yields can lead to high unit costs.
② Extraction and purification can be complex and require tight control of oxidative stability.
(2) Breakthrough Directions
① Metabolic engineering to increase flux and tolerance.
② Process integration with downstream separation to reduce solvent demand and thermal history.
III. Purification and Formulation-Grade Quality Construction
3.1 Purification Technology System
Purification targets are not limited to high assay; they also include a controllable impurity profile, stable color, compliant residual solvents, and stereochemical specifications when applicable.
(1) Recrystallization and Solvent-System Selection
① Selective dissolution–crystallization can enrich the main component and exclude impurities.
② Solvent systems should balance solubility discrimination, recyclability, and regulatory compliance.
(2) Decolorization and Trace-Impurity Removal
① For batches sensitive to color and oxidative byproducts, adsorption-based decolorization can be considered, while controlling potency loss and preventing introduction of new impurities.
(3) Drying and Packaging
① Low-temperature drying, light protection, and inert-gas shielding can reduce oxidation and degradation.
② Packaging materials should provide barrier performance to limit light and oxygen permeation.
3.2 Stability Control and Formulation Compatibility Foundations
Given sensitivity to light, alkaline conditions, and metal-ion catalysis, formulation-grade products require a stability closed loop spanning both raw-material control and formulation design.
(1) Upstream (Raw-Material) Controls
① Control water content, peroxide-related attributes, and trace metals.
② Establish accelerated testing and shelf-life modeling to manage batch-to-batch variability.
(2) Downstream (Formulation) Controls
① Control pH windows and use chelators or synergistic antioxidant systems to reduce degradation.
② Use inclusion complexes, liposomes/microemulsions, or solid dispersions to improve dissolution and stability consistency.
IV. Quality Standards and Analytical Methods
4.1 Core Quality Attributes
Quality priorities vary by use case (pharmaceuticals, supplements, cosmetic ingredients, animal nutrition, etc.), but the core framework typically covers assay, impurities, residues, and stereochemistry.
(1) Assay and Related Substances
① Assay is a primary release attribute.
② Related-substance profiling controls synthetic and oxidative byproducts to support long-term stability and safety.
(2) Optical Purity and R/S Ratio
① For R-α-lipoic acid products, optical purity or R-content should be controlled.
② Stereochemical control is directly associated with efficacy consistency and batch-to-batch variability risk.
(3) Residual Solvents and Elemental Impurities
① Residual solvents should meet applicable regulatory limits.
② Trace metals can catalyze oxidative degradation and should be treated as stability-critical factors.
(4) Physicochemical and Stability-Related Indices
① Water content, melting point/range, specific rotation (when applicable), and color.
② Degradation behavior under light/thermal/humidity stress informs storage and logistics specifications.
4.2 Representative Analytical Methods
(1) Assay and Related Substances
① HPLC is commonly used for assay determination and impurity profiling in batch release and stability studies.
(2) Chiral Separation and Optical Purity
① Chiral HPLC supports R/S quantification and optical-purity assessment and is a key method for high-end applications.
(3) Residual Solvents and Elemental Impurities
① Gas chromatography is used for residual-solvent testing.
② ICP-OES/ICP-MS or atomic absorption is used for elemental impurity control.
(4) Structural Confirmation and Degradation-Product Studies
① During R&D and change-validation phases, LC–MS and NMR can be used for structural confirmation and degradation-mechanism analysis.
V. Application Domains and Engineering Expansion
5.1 Pharmaceuticals
Pharmaceutical use is commonly aligned with metabolic-support and oxidative-stress-management contexts, and it is also frequently encountered in research and use cases related to nervous-system indications.
(1) Formulation Engineering Essentials
① Due to limited water solubility, oral dosage forms often employ salt formation, solid dispersions, or inclusion complexes to improve dissolution and bioavailability.
② Given photosensitivity and oxidation susceptibility, light-protective packaging, antioxidant systems, and low-metal control are important for shelf-life assurance.
5.2 Dietary Supplements and Nutrition
α-Lipoic acid is widely used in antioxidant and energy-metabolism formulations; these products likewise benefit from consistent raw-material quality and a controlled impurity profile.
(1) Application Considerations
① Racemic products and R-form products differ materially in positioning and cost; selection should align with target populations and compliant claim pathways.
② When co-formulated with vitamin C/E or coenzyme Q-type ingredients, attention is required for redox-environment coupling and stability interactions.
5.3 Cosmetics
In cosmetics, α-lipoic acid is used in antioxidant and skin-condition management concepts, where key formulation challenges include stability and irritation-boundary control.
(1) Formulation Engineering Essentials
① Control pH and trace metals to reduce discoloration and off-odor formation.
② Use inclusion or carrier-based strategies to reduce irritation potential and improve stability and sensorial consistency.
5.4 Animal Nutrition and Feed
In animal nutrition, α-lipoic acid is explored in formulations for antioxidant support and stress management.
(1) Engineering Considerations
① Evaluate the impacts of feed-processing thermal history and storage conditions on α-lipoic acid stability.
② Establish suitable inclusion windows by species and growth stage, and assess synergy/substitution relationships with other antioxidant systems.
VI. Trends and Future Directions
6.1 Green Processes and Low-Carbon Manufacturing
Green transformation will likely focus on solvent substitution, closed-loop recycling, and resource recovery for salt streams and sulfur-containing effluents.
(1) Priority Directions
① Increase route selectivity to reduce byproducts and purification burdens.
② Optimize solvent-recovery systems to reduce solvent footprint and emission pressure per unit product.
③ Implement continuous reaction and continuous crystallization to improve stability and consistency and reduce batch-to-batch variability.
6.2 High-Purity R-Form Products and Application-Specific Grades
With growth in high-end pharmaceutical and precision-formulation demand, application-specific grades of R-α-lipoic acid increasingly emphasize integrated control of stereochemistry, impurity profile, and stability.
(1) Priority Directions
① More economical stereochemical-control strategies to reduce resolution losses and cost.
② Quantitative evaluation frameworks linking R-content to clinical/functional performance to support grade definition and specification rationales.
6.3 Formulation Engineering and Delivery-System Upgrades
In end-use applications, key bottlenecks often lie not in “whether it works,” but in “whether it is stable, absorbable, and reproducible.”
(1) Priority Directions
① Use inclusion complexes, solid dispersions, and liposomes/microemulsions to improve dissolution and bioavailability.
② Apply antioxidant-network design and metal-ion management to mitigate discoloration, off-odor, and potency decay.
③ Build scenario-oriented standardized formulations and process windows to reduce scale-up and deployment risk.
VII. Aladdin-Related Products
A. α-Lipoic Acid (LA)
Catalog No. | Product Name | CAS No. | Specifications or Purity |
(R)-(+)-α-Lipoic acid | 1200-22-2 | Moligand™, ≥98% | |
(R)-(+)-α-Lipoic acid | 1200-22-2 | Moligand™, 10 mM in DMSO | |
(S)-(-)-α -Lipoic acid | 1077-27-6 | ≥97% (HPLC) | |
DL-Thioctic acid | 1077-28-7 | ≥99% |
B. Reduced Form of α-Lipoic Acid: Dihydrolipoic Acid (DHLA)
Catalog No. | Product Name | CAS No. | Specifications or Purity |
Dihydrolipoic Acid | 462-20-4 | Moligand™, 10 mM in DMSO | |
Dihydrolipoic Acid | 462-20-4 | Moligand™, ≥97% |
C. Small-Molecule Derivatives of α-Lipoic Acid: Substituted/Activated/Isotope-Labeled
Catalog No. | Product Name | CAS No. | Specifications or Purity |
4'-NITROSUCCINANILIC ACID | 5502-63-6 | — | |
DL-α-Lipoic Acid-NHS | 40846-94-4 | ≥96% | |
rac α-Lipoic Acid-d5 | 1189471-66-6 | — | |
Lipoic acid-d | 1448263-85-1 | — |
D. PEG Conjugates/Derivatives (LA–PEG / mPEG–LA)
Catalog No. | Product Name | Specifications or Purity |
mPEG2K-Thioctic acid | average Mₙ 2000 | |
Lipoic acid PEG NHS, LA-PEG-NHS | MW 10000 Da | |
Lipoic acid PEG NHS, LA-PEG-NHS | MW 2000 Da | |
Lipoic acid PEG NHS, LA-PEG-NHS | MW 5000 Da | |
Lipoic acid PEG Biotin, LA-PEG-Biotin | MW 5000 Da | |
Lipoic acid PEG Biotin, LA-PEG-Biotin | MW 3400 Da | |
Lipoic acid PEG Biotin, LA-PEG-Biotin | MW 2000 Da | |
Lipoic acid PEG OH, LA-PEG-OH | MW 5000 Da | |
Lipoic acid PEG acid, LA-PEG-COOH | MW 2000 Da | |
Lipoic acid PEG acid, LA-PEG-COOH | MW 10000 Da | |
Lipoic acid PEG acid, LA-PEG-COOH | MW 3400 Da | |
Lipoic acid PEG acid, LA-PEG-COOH | MW 5000 Da | |
Lipoic acid PEG amine, LA-PEG-NH2 | MW 5000 Da | |
Lipoic acid PEG amine, LA-PEG-NH2 | MW 2000 Da | |
Lipoic acid PEG amine, LA-PEG-NH2 | MW 3400 Da | |
Lipoic acid PEG amine, LA-PEG-NH2 | MW 20000 Da | |
Lipoic acid PEG amine, LA-PEG-NH2 | MW 1000 Da | |
Lipoic acid PEG amine, LA-PEG-NH2 | MW 10000 Da | |
Lipoic acid PEG Maleimide, LA-PEG-Mal | MW 3400 Da | |
Lipoic acid PEG, mPEG-LA | MW 40000 Da | |
Lipoic acid PEG, mPEG-LA | MW 2000 Da | |
Lipoic acid PEG, mPEG-LA | MW 20000 Da | |
Lipoic acid PEG, mPEG-LA | MW 1000 Da | |
Lipoic acid PEG, mPEG-LA | MW 5000 Da | |
Lipoic acid PEG, mPEG-LA | MW 10000 Da | |
Lipoic acid PEG, mPEG-LA | MW 30000 Da |
With its reversible redox cycling enabled by the 1,2-dithiolane ring, α-lipoic acid integrates cofactor functionality in energy metabolism with broad antioxidant-network modulation, making it an important functional ingredient across pharmaceuticals, nutrition, and personal care. Industrial production is largely chemical-synthesis based, with core technical priorities centered on selective dithiolane construction, convergence of impurity profiles, compliant residual-solvent control, and stability management. For high-end applications, R-form content and optical-purity control become additional critical specifications. Looking forward, continued evolution is expected along the axes of greener manufacturing, more economical stereochemical control, and upgraded delivery systems, supported by an integrated quality framework spanning raw materials, scale-up, formulation engineering, and standardized analytics.
Aladdin: https://www.aladdinsci.com/